Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

References

• Cognetti DM, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113:1911–1932.
   PubMed Web of Science ®Google Scholar
• Jemal A., Siegel R., Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71–96.
   PubMed Web of Science ®Google Scholar
• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008; 83:489–501.
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Chi A, Nguyen LM, et al. Human papillomavirus-associated oropharyngeal cancer: a new clinical entity. QJM. 2010; 103:229–236.
   PubMedGoogle Scholar
• Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010; 39:166–181.
   PubMed Web of Science ®Google Scholar
• Goon PK, Stanley MA, Ebmeyer J, et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol. 2009; 1:36.
   PubMedGoogle Scholar
• Lallemant B, Evrard A, Combescure C, et al. Clinical relevance of nine transcriptional molecular markers for the diagnosis of head and neck squamous cell carcinoma in tissue and saliva rinse. BMC Cancer. 2009; 9:370.
   PubMed Web of Science ®Google Scholar
• Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008; 359:1143–1154.
   PubMed Web of Science ®Google Scholar
• Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008; 112:2635–2645.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355:949–955.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Fountzilas G. Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. Med Oncol. 2006; 23:1–15.
   PubMed Web of Science ®Google Scholar
• Tsao AS, Garden AS, Kies MS, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006; 24:4163–4169.
   Google Scholar
• Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2010; 17:17.
   Google Scholar
• Shinoto M, Shioyama Y, Sasaki T, et al. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer. Am J Clin Oncol. 2010; 3:3.
   Google Scholar
• Choi BD, Archer GE, Mitchell DA, EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009; 19:713–723.
   PubMed Web of Science ®Google Scholar
• Li G, Mitra S, Wong AJ. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Neurosurg Clin N Am. 2010; 21:87–93.
   PubMed Web of Science ®Google Scholar
• Li G, Wong AJ. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines. 2008; 7:977–985.
   PubMed Web of Science ®Google Scholar
• Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011; 207:337–342.
   PubMed Web of Science ®Google Scholar
• Valentini AM, Pirrelli M, Caruso ML. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Curr Opin Mol Ther. 2008; 10:124–131.
   PubMedGoogle Scholar
• Wikstr CJ, Hale LP, Batra SK, Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995; 55:3140–3148.
   PubMedGoogle Scholar
• Tinhofer I, Klinghammer K, Weichert W, Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 2011; 17:5197–5204.
   PubMed Web of Science ®Google Scholar
• Ochiai H, Archer GE, Herndon JE, 2nd, EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4 +and CD8+ T cells. Cancer Immunol Immunother. 2008; 57:115–121.
   PubMed Web of Science ®Google Scholar
• Dreier A, Barth S, Goswami A, Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance? Tumour Biol. 2011; 11:11.
   Google Scholar
• Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007; 39:271–278,
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Kufer P, Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009; 11:22–30.
   PubMedGoogle Scholar
• Wolf E, Hofmeister R, Kufer P, BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today. 2005; 10:1237–1244.
   PubMed Web of Science ®Google Scholar
• Lutterbuese R, Schaller E, Burghart E, Sriskandarajah M, Raum T, Rau D, Mangold S, Cierpka R, Guller B, Lutterbuese P, Baeuerle PA, Kufer P. Conversion of cetuximab, panitumumab, trastuzumab and omalizumab into T-cell-engaging BiTE antibodies creates novel drug candidates of high potency. Proc Am Assoc Cancer Res. 2008; 99: Abs 2402.
   Google Scholar
• Tijink BM, Buter J, R de Bree, A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006; 12:6064–6072.
   PubMed Web of Science ®Google Scholar
• Sauter A, Kloft C, Gronau S, Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol. 2007; 30:927–935.
   PubMed Web of Science ®Google Scholar
• Van Hal NL, Van Dongen GA, Ten Brink CB, Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. Cancer Immunol Immunother. 1997; 45:88–92.
   PubMedGoogle Scholar
• Colnot DR, Ossenkoppele GJ, Roos JC, Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res. 2002; 8:3401–3406.
   PubMed Web of Science ®Google Scholar
• Borjesson PK, Postema EJ, Roos JC, Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003; 9:3961S–3972S.
   PubMed Web of Science ®Google Scholar
• Mackay CR, Terpe HJ, Stauder R, Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994; 124:71–82.
   PubMed Web of Science ®Google Scholar
• Rupp U, Schoendorf-Holl E, Eichbaum M, Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs. 2007; 18:477–485.
   PubMed Web of Science ®Google Scholar
• Platt VM, Szoka FC, Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008; 5:474–486.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci U S A. 2008; 105:12643–12644.
   PubMed Web of Science ®Google Scholar
• M Chiriva-Internati, Cobos E, Kast WM. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol. 2007; 26:197–222.
   PubMed Web of Science ®Google Scholar
• Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009; 2009:346345.
   PubMedGoogle Scholar
• Chiriva-Internati M, Yu Y, Mirandola L, Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 2010; 5:e10471.
   PubMed Web of Science ®Google Scholar
• Weinert BT, Krishnadath KK, Milano F, Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine. Cancer Immun. 2009; 9:9.
   PubMedGoogle Scholar
• Boni A, Muranski P, Cassard L, Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 2008; 112:4746–4754.
   PubMed Web of Science ®Google Scholar
• U. S. N. I. o. Health. Clinical Trials. Vol. 2010; 2010.
   Google Scholar
• Wolf FWGT, Dolan R. IRX-2: promising new immunotherapy for head and neck cancer. Proceeding of 7th internation Conference on Head and Neck Cancer of American Head and Neck Society. San Francisco, Calif, USA; 2008.
   Google Scholar
• Chiriva-Internati M, Liu Y, Salati E, Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol. 2002; 32:30–38.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science. 2004; 305:197–200.
   PubMed Web of Science ®Google Scholar
• Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst. 2010; 102:1108–1110.
   PubMedGoogle Scholar
• Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010; 10:580–593.
   PubMed Web of Science ®Google Scholar
• Higano CS, Small EJ, Schellhammer P, Sipuleucel-T. Nat Rev Drug Discov. 2010; 9:513–514.
   PubMed Web of Science ®Google Scholar
• Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet. 2009; 373:673–683.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23:2346–2357.
   PubMed Web of Science ®Google Scholar
• Gervois N, Heuze F, Diez E, Selective expansion of a specific anti-tumor CD8 +cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol. 1990; 20:825–831.
   PubMedGoogle Scholar
• Melief CJ, Kast WM. T-cell immunotherapy of cancer. Res Immunol. 1991; 142:425–429.
   PubMedGoogle Scholar
• Wong RA, Alexander RB, Puri RK, In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice. J Immunother. 1991; 10:120–130.
   PubMed Web of Science ®Google Scholar
• Yang JC, Rosenberg SA. Current approaches to the adoptive immunotherapy of cancer. Adv Exp Med Biol. 1988; 233:459–467.
   PubMedGoogle Scholar
• Junker N, Andersen MH, Wenandy L, Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy. 2011; 13:822–834.
   PubMed Web of Science ®Google Scholar
• Scholten KB, Turksma AW, Ruizendaal JJ, Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med. 2011; 9:147.
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Liu K, Dudley ME, Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008; 19:496–510.
   PubMed Web of Science ®Google Scholar
• Wrzesinski C, Paulos CM, Kaiser A, Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010; 33:1–7.
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli A, CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005; 174:2591–2601.
   PubMed Web of Science ®Google Scholar
• Gillison ML, G D'Souza, Westra W, Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008; 100:407–420.
   PubMed Web of Science ®Google Scholar
• Rampias T, Sasaki C, Weinberger P, E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009; 101:412–423.
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363:24–35.
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S, Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 100:261–269.
   PubMed Web of Science ®Google Scholar
• Dayyani F, Etzel CJ, Liu M, Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010; 2:15.
   PubMedGoogle Scholar
• Kumar B, Cordell KG, Lee JS, EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008; 26:3128–3137.
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Ridge JA, Gillison ML, Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009; 31:1393–1422.
   PubMedGoogle Scholar
• Munoz N, Manalastas R Jr, Pitisuttithum P, Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373:1949–1957.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301–314.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A, Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine. 2009; 27:581–587.
   PubMed Web of Science ®Google Scholar
• Munoz N, Kjaer SK, Sigurdsson K, Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102:325–339.
   PubMed Web of Science ®Google Scholar
• Palefsky JM. Human Papillomavirus-related disease in men: not just a women's issue. J Adolescent Health. 2010; 46:S12–S19.
   PubMed Web of Science ®Google Scholar
• Kaneno R, Shurin GV, Tourkova IL, Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med. 2009; 7:58.
   PubMed Web of Science ®Google Scholar
• Gelbard A, Garnett CT, Abrams SI, Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res. 2006; 12:1897–1905.
   PubMed Web of Science ®Google Scholar
• Grubeck-Loebenstein B, Della Bella S, Iorio AM, Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009; 21:201–209.
   PubMed Web of Science ®Google Scholar
• Shurin MR, Shurin GV, Chatta GS. Aging and the dendritic cell system: implications for cancer. Crit Rev Oncol Hematol. 2007; 64:90–105.
   PubMed Web of Science ®Google Scholar
• Ressing ME, van Driel WJ, Brandt RM, Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother. 2000; 23:255–266.
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Ressing ME, Kenter GG, Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 1999; 35:946–952.
   PubMed Web of Science ®Google Scholar
• Warrino DE, Olson WC, Knapp WT, Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res. 2004; 10:3301–3308.
   PubMed Web of Science ®Google Scholar
• Dallal RM, Lotze MT. Immunotherapy of metastasis. Surg Oncol Clin N Am. 2001; 10:433–447.
   PubMedGoogle Scholar
• Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Identification and characterization of a peptide with affinity to head and neck cancer. J Nucl Med. 2009; 50:426–434.
   PubMedGoogle Scholar
• Walsh JE, Lathers DM, Chi AC, Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol. 2007; 8:227–238.
   PubMedGoogle Scholar
• Choi P, Jordan CD, Mendez E, Examination of oral cancer biomarkers by tissue microarray analysis. Arch Otolaryngol Head Neck Surg. 2008; 134:539–546.
   PubMed Web of Science ®Google Scholar
• Han J, Kioi M, Chu WS, Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol. 2009; 1:27.
   Google Scholar
• Lee PS, Teaberry VS, Bland AE, Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer. 2010; 126:1378–1389.
   PubMedGoogle Scholar
• Muller-Richter UD, Dowejko A, Reuther T, Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines. Head Face Med. 2009; 5:10.
   PubMedGoogle Scholar
• Online CTDatabase. Vol. 2010: Ludwig Institute for Cancer Research; 2010.
   Google Scholar